STAAR Stockholders Have a Choice: Vote FOR Alcons Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today issued the following open letter to...